Kezar Life Sciences, Inc. (NASDAQ:KZR) Short Interest Update

Kezar Life Sciences, Inc. (NASDAQ:KZR) saw a significant increase in short interest in September. As of September 30th, there was short interest totalling 982,900 shares, an increase of 13.6% from the September 15th total of 865,600 shares. Based on an average daily volume of 834,500 shares, the days-to-cover ratio is currently 1.2 days.

Kezar Life Sciences Stock Performance

Shares of NASDAQ KZR opened at $0.87 on Wednesday. Kezar Life Sciences has a 1-year low of $0.52 and a 1-year high of $1.14. The company has a debt-to-equity ratio of 0.05, a current ratio of 9.58 and a quick ratio of 9.58. The business’s 50 day moving average is $0.64 and its two-hundred day moving average is $0.69. The stock has a market capitalization of $63.34 million, a P/E ratio of -0.62 and a beta of 0.21.

Kezar Life Sciences (NASDAQ:KZR) last released its earnings results on Tuesday, August 13th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.04. As a group, research analysts expect that Kezar Life Sciences will post -1.2 EPS for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “neutral” rating on shares of Kezar Life Sciences in a research report on Monday.

Hedge Funds Weigh In On Kezar Life Sciences

Large investors have recently made changes to their positions in the company. Fidelis Capital Partners LLC bought a new stake in Kezar Life Sciences in the first quarter worth about $25,000. Mackenzie Financial Corp purchased a new stake in shares of Kezar Life Sciences in the second quarter worth approximately $35,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Kezar Life Sciences during the 2nd quarter worth approximately $63,000. Marquette Asset Management LLC purchased a new position in Kezar Life Sciences during the 1st quarter valued at $114,000. Finally, BNP Paribas Financial Markets grew its position in Kezar Life Sciences by 35.4% in the 1st quarter. BNP Paribas Financial Markets now owns 273,430 shares of the company’s stock valued at $247,000 after acquiring an additional 71,543 shares during the last quarter. 67.90% of the stock is owned by hedge funds and other institutional investors.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.